Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

Document › Details

Sygnis Pharma AG. (12/20/12). "Press Release: Sygnis Announces the Adaptation of Its Organisation to the New Business Activity". Heidelberg.

	Region	Heidelberg
	Country	Germany
	Organisation	Sygnis Pharma AG
	Today	Sygnis AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard)
	Group	Expedeon (Group)
	Organisation 2	X-Pol Biotech S.L
	Group	Expedeon (Group)
	Product	pharmaceutical
	Product 2	molecular biology
	Index term 2	Genetrix (ES)–Sygnis: investment, 201207–201212 acquisition of X-Pol by Sygnis via reverse merger w X-Pol holding 77.5% of Sygnis after closing
	Person	Willinger, Peter (Apogenix 201506– CFO before Sygnis Pharma + Lion Bioscience)

SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03, Prime Standard) announced today the discontinuation of its therapeutic R&D project KIBRA and the adaptation of its organisation to the new business activity. At the Heidelberg site the staff will be reduced by 10 employees. These measures are implemented to concentrate the financial resources on the development and marketing of novel technologies in molecular biology in line with the new corporate strategy. This new business was acquired in 2012 by joining forces with the Spanish X-Pol Biotech.

Peter Willinger, Chief Financial Officer, stated: "Despite good progress in the project, an outlicensing of the KIBRA project was unfortunately not possible within the available timeline. The KIBRA project can not be continued with internal resources. The realignment of the company regrettably makes a staff reduction necessary. I would like to extend my sincere gratitude to all employees affected for their excellent work for SYGNIS."

For further information please contact:
SYGNIS Pharma AG
Peter Willinger
CFO
SYGNIS Pharma AG
Tel.: +49 6221 454 836
E-mail: peter.willinger@sygnis.de

About SYGNIS Pharma AG: www.sygnis.de

SYGNIS Pharma AG (Heidelberg, Germany) is a biotech company listed in the Prime Standard of the German Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03). According to the 2012 newly defined business strategy, the company focuses on the development and marketing of novel technologies in molecular biology, e.g. in the field of DNA amplification and sequencing. For the key product "Qualiphi®", an improved polymerase for amplifying DNA, an exclusive worldwide license has been granted to Qiagen in July 2012.

### Disclaimer

Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###

Heidelberg, Germany
SYGNIS Pharma AG, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany, www.sygnis.de, Tel: +49-6221-454-6, Fax: +49-6221-454-700

Record changed: 2017-04-02

More documents for Expedeon (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)